5 completed, 1 terminated. 3 Phase 3, 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow BioVex Limited: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer Talimogene Laherparepvec, Radiation, Cisplatin - Squamous Cell Carcinoma, Head and Neck Cancer | Phase 3 | Terminated | BioVex Limited | 5 | 2011-02-01 | 2016-02-08 |
| An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma Talimogene Laherparepvec, Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) - Melanoma | Phase 3 | Completed | BioVex Limited | 31 | 2010-10-01 | 2015-12-18 |
| Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma Talimogene laherparepvec, GM-CSF - Melanoma | Phase 3 | Completed | BioVex Limited | 437 | 2009-04-01 | 2016-07-13 |
| An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016) Talimogene Laherparepvec - Melanoma | Phase 2 | Completed | BioVex Limited | 3 | 2008-08-01 | 2015-12-17 |
| Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer Talimogene Laherparepvec - Pancreatic Cancer | Phase 1 | Completed | BioVex Limited | 17 | 2006-11-01 | 2016-04-15 |
| A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma Talimogene Laherparepvec - Melanoma | Phase 2 | Completed | BioVex Limited | 50 | 2005-12-01 | 2015-12-18 |
Melanoma (4) · Adenocarcinoma (1) · Carcinoma, Squamous Cell (1) · Head and Neck Neoplasms (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1)
talimogene laherparepvec (6) · Granulocyte-Macrophage Colony-Stimulating Factor (2) · Cisplatin (1) · Colony-Stimulating Factors (1) · Radiation (1) · sargramostim (1)
United States (5) · United Kingdom (4) · Canada (1) · South Africa (1)
John Nemunaitis, MD (1) · Kevin Harrington, MD (1) · Neil N Senzer, MD (1) · Rob Coffin, PhD (1) · Robert Coffin, PhD (1)
PMID 26014293, PMID 28923101, PMID 31171039
2008 (1)